JP2005533835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533835A5 JP2005533835A5 JP2004520132A JP2004520132A JP2005533835A5 JP 2005533835 A5 JP2005533835 A5 JP 2005533835A5 JP 2004520132 A JP2004520132 A JP 2004520132A JP 2004520132 A JP2004520132 A JP 2004520132A JP 2005533835 A5 JP2005533835 A5 JP 2005533835A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- aryl
- pharmaceutical composition
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 39
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 125000003118 aryl group Chemical group 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 238000000034 method Methods 0.000 claims 23
- 125000003342 alkenyl group Chemical group 0.000 claims 20
- 125000002877 alkyl aryl group Chemical group 0.000 claims 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims 20
- 125000003710 aryl alkyl group Chemical group 0.000 claims 18
- 241001465754 Metazoa Species 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 10
- 239000008024 pharmaceutical diluent Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 101100240529 Caenorhabditis elegans nhr-25 gene Proteins 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- 101100240523 Caenorhabditis elegans nhr-19 gene Proteins 0.000 claims 1
- 101150073133 Cpt1a gene Proteins 0.000 claims 1
- 102000015303 Fatty Acid Synthases Human genes 0.000 claims 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 claims 1
- 101710151321 Melanostatin Proteins 0.000 claims 1
- 102400000064 Neuropeptide Y Human genes 0.000 claims 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 claims 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 0 CCCCC=CC=C[C@@](C)(*1)C(O)=CC1=O Chemical compound CCCCC=CC=C[C@@](C)(*1)C(O)=CC1=O 0.000 description 14
- JSGMQNCACRMGPO-UHFFFAOYSA-N CCCCCCOC(C(CC)C1)=CC1=O Chemical compound CCCCCCOC(C(CC)C1)=CC1=O JSGMQNCACRMGPO-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39458502P | 2002-07-09 | 2002-07-09 | |
| PCT/US2003/021700 WO2004005277A1 (en) | 2002-07-09 | 2003-07-09 | Novel compunds, pharmaceutical compositions containing same, and methods of use for same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010228956A Division JP2011037881A (ja) | 2002-07-09 | 2010-10-08 | 新規の化合物、それを含有する医薬組成物、およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005533835A JP2005533835A (ja) | 2005-11-10 |
| JP2005533835A5 true JP2005533835A5 (https=) | 2007-10-04 |
Family
ID=30115739
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004520132A Pending JP2005533835A (ja) | 2002-07-09 | 2003-07-09 | 新規の化合物、それを含有する医薬組成物、およびその使用方法 |
| JP2010228956A Pending JP2011037881A (ja) | 2002-07-09 | 2010-10-08 | 新規の化合物、それを含有する医薬組成物、およびその使用方法 |
| JP2013117677A Pending JP2013189464A (ja) | 2002-07-09 | 2013-06-04 | 新規の化合物、それを含有する医薬組成物、およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010228956A Pending JP2011037881A (ja) | 2002-07-09 | 2010-10-08 | 新規の化合物、それを含有する医薬組成物、およびその使用方法 |
| JP2013117677A Pending JP2013189464A (ja) | 2002-07-09 | 2013-06-04 | 新規の化合物、それを含有する医薬組成物、およびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7649012B2 (https=) |
| EP (3) | EP2386551A1 (https=) |
| JP (3) | JP2005533835A (https=) |
| KR (1) | KR101087559B1 (https=) |
| CN (2) | CN100513404C (https=) |
| AU (1) | AU2003265267B2 (https=) |
| BR (1) | BRPI0312649A2 (https=) |
| CA (2) | CA2767092C (https=) |
| EA (1) | EA013371B1 (https=) |
| IL (2) | IL166108A0 (https=) |
| MX (1) | MXPA05000365A (https=) |
| SG (1) | SG169236A1 (https=) |
| WO (1) | WO2004005277A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1471906A4 (en) | 2002-02-08 | 2006-02-01 | Univ Johns Hopkins Med | STIMULATION OF CPT-1 TO REDUCE BODY WEIGHT |
| JP4493494B2 (ja) * | 2002-07-09 | 2010-06-30 | ファスゲン，インク． | ヒトおよび動物における微生物感染症の治療方法 |
| EP2386551A1 (en) * | 2002-07-09 | 2011-11-16 | Fasgen Inc. | Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| CN101022792A (zh) * | 2004-05-26 | 2007-08-22 | 法斯根有限责任公司 | 新化合物、包含该化合物的药物组合物及该化合物的应用方法 |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| JP2010509335A (ja) * | 2006-11-08 | 2010-03-25 | ファスゲン エルエルシー | 新規の化合物、それを含有する医薬組成物、及びその使用方法 |
| WO2008059214A1 (en) * | 2006-11-13 | 2008-05-22 | Astrazeneca Ab | Bisamlde derivatives and use thereof as fatty acid synthase inhibitors |
| WO2009149066A1 (en) * | 2008-06-02 | 2009-12-10 | Fasgen, Inc. | Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| WO2010118324A2 (en) | 2009-04-09 | 2010-10-14 | Nuclea Biotechnologies, LLC | Antibodies against fatty acid synthase |
| US9149445B2 (en) | 2009-07-27 | 2015-10-06 | The Trustees Of Princeton University | Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections |
| MX2012001729A (es) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| EP3159331A1 (en) | 2010-05-05 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012135027A2 (en) * | 2011-03-25 | 2012-10-04 | The Research Foundation Of State University Of New York | Thiolactone antibiotics |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| AU2013280980B2 (en) | 2012-06-25 | 2017-10-19 | Thomas Jefferson University | Compositions and methods for treating cancer with aberrant lipogenic signaling |
| JP6285442B2 (ja) * | 2012-09-07 | 2018-02-28 | ヤンセン ファーマシューティカ エヌ．ベー． | がん治療用の脂肪酸合成酵素（ｆａｓｎ）阻害剤として有用なイミダゾリン−５−オン誘導体 |
| SG10201707409PA (en) | 2013-03-13 | 2017-10-30 | Forma Therapeutics Inc | Novel compounds and compositions for inhibition of fasn |
| WO2016079317A1 (en) | 2014-11-20 | 2016-05-26 | Vib Vzw | Means and methods for treatment of early-onset parkinson's disease |
| US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| CN114480521B (zh) * | 2020-11-13 | 2024-07-26 | 中国科学院青岛生物能源与过程研究所 | 一种三氮菌素c的制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3496187A (en) * | 1967-03-20 | 1970-02-17 | American Home Prod | N-(heterocyclyl)aconamides |
| US3472878A (en) * | 1969-01-27 | 1969-10-14 | American Home Prod | N-(hydroxyaryl)aconamides |
| JPS5859920A (ja) * | 1981-10-05 | 1983-04-09 | Chugai Pharmaceut Co Ltd | 生体防禦能賦活剤 |
| US4565699A (en) * | 1983-07-18 | 1986-01-21 | The Upjohn Company | Composition of matter and process |
| US4720503A (en) * | 1985-08-02 | 1988-01-19 | Merck & Co., Inc. | N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors |
| CH667655A5 (de) * | 1986-09-24 | 1988-10-31 | Lonza Ag | Verfahren zur herstellung von 4-alkoxy-2(5h)-thiophenonen. |
| US4753871A (en) * | 1986-12-12 | 1988-06-28 | Eastman Kodak Company | Cyan dye-forming couplers and photographic materials containing same |
| AU1044088A (en) * | 1986-12-17 | 1988-07-15 | Nippon Soda Co., Ltd. | Heterocyclic compounds having triketo skeleton |
| US5665874A (en) * | 1989-01-17 | 1997-09-09 | John Hopkins University | Cancer related antigen |
| US5759837A (en) | 1989-01-17 | 1998-06-02 | John Hopkins University | Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway |
| US5759791A (en) * | 1989-01-17 | 1998-06-02 | The Johns Hopkins University | Cancer related antigen |
| US5679801A (en) * | 1991-04-12 | 1997-10-21 | American Home Products Corporation | Tetronic and thiotetronic acid derivatives as phospholipase A2 inhibitors |
| US5614551A (en) | 1994-01-24 | 1997-03-25 | The Johns Hopkins University | Inhibitors of fatty acid synthesis as antimicrobial agents |
| CN1131209C (zh) * | 1995-05-09 | 2003-12-17 | 拜尔公司 | 可用作杀虫剂和除草剂的烷基－二卤代苯基取代的酮烯醇 |
| US5981575A (en) | 1996-11-15 | 1999-11-09 | Johns Hopkins University, The | Inhibition of fatty acid synthase as a means to reduce adipocyte mass |
| JPH10212284A (ja) * | 1996-11-27 | 1998-08-11 | Sagami Chem Res Center | テトロン酸−３−カルボン酸誘導体、その製造方法、製造中間体、抗がん剤、及び蛋白脱リン酸化酵素阻害剤 |
| US6391912B1 (en) * | 1996-12-12 | 2002-05-21 | Bayer Aktiengesellschaft | Substituted phenylketoenols |
| CO4970714A1 (es) * | 1997-09-05 | 2000-11-07 | Boehringer Mannheim Gmbh | Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h) tiofenonas como agentes antitumorales |
| HN2000000051A (es) * | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | Derivados heterociclicos utiles como agentes anticancerosos |
| IT1315267B1 (it) * | 1999-12-23 | 2003-02-03 | Novuspharma Spa | Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale |
| GB0000131D0 (en) * | 2000-01-06 | 2000-02-23 | Univ Cardiff | Thiolactomycin analogues,compositions containing the same and uses thereof |
| US6376682B1 (en) * | 2000-02-01 | 2002-04-23 | Takama System, Ltd. | Compound with α-glucosidase inhibiting action and method for producing the same |
| MY134040A (en) | 2001-05-02 | 2007-11-30 | Univ New York | Inhibition of pigmentation by inhibition of fatty acid synthase |
| EP1471906A4 (en) * | 2002-02-08 | 2006-02-01 | Univ Johns Hopkins Med | STIMULATION OF CPT-1 TO REDUCE BODY WEIGHT |
| EP2386551A1 (en) * | 2002-07-09 | 2011-11-16 | Fasgen Inc. | Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| JP4493494B2 (ja) | 2002-07-09 | 2010-06-30 | ファスゲン，インク． | ヒトおよび動物における微生物感染症の治療方法 |
| US9690894B1 (en) | 2015-11-02 | 2017-06-27 | Altera Corporation | Safety features for high level design |
-
2003
- 2003-07-09 EP EP11164126A patent/EP2386551A1/en not_active Withdrawn
- 2003-07-09 KR KR1020057000382A patent/KR101087559B1/ko not_active Expired - Fee Related
- 2003-07-09 SG SG200806632-6A patent/SG169236A1/en unknown
- 2003-07-09 MX MXPA05000365A patent/MXPA05000365A/es active IP Right Grant
- 2003-07-09 WO PCT/US2003/021700 patent/WO2004005277A1/en not_active Ceased
- 2003-07-09 JP JP2004520132A patent/JP2005533835A/ja active Pending
- 2003-07-09 EP EP11164123A patent/EP2386550A1/en not_active Withdrawn
- 2003-07-09 US US10/520,505 patent/US7649012B2/en not_active Expired - Fee Related
- 2003-07-09 EP EP03763470A patent/EP1539730A4/en not_active Withdrawn
- 2003-07-09 AU AU2003265267A patent/AU2003265267B2/en not_active Ceased
- 2003-07-09 EA EA200500178A patent/EA013371B1/ru not_active IP Right Cessation
- 2003-07-09 CN CNB038185563A patent/CN100513404C/zh not_active Expired - Fee Related
- 2003-07-09 CA CA2767092A patent/CA2767092C/en not_active Expired - Fee Related
- 2003-07-09 CA CA2491802A patent/CA2491802C/en not_active Expired - Fee Related
- 2003-07-09 CN CN200910203849.8A patent/CN101602756B/zh not_active Expired - Fee Related
- 2003-07-09 BR BRPI0312649A patent/BRPI0312649A2/pt not_active IP Right Cessation
-
2005
- 2005-01-03 IL IL16610805A patent/IL166108A0/xx unknown
-
2008
- 2008-03-17 IL IL190218A patent/IL190218A0/en unknown
-
2010
- 2010-01-13 US US12/686,691 patent/US20100120901A1/en not_active Abandoned
- 2010-10-08 JP JP2010228956A patent/JP2011037881A/ja active Pending
-
2013
- 2013-06-04 JP JP2013117677A patent/JP2013189464A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533835A5 (https=) | ||
| JP2002539181A5 (https=) | ||
| JP2009536660A5 (https=) | ||
| JP2010530881A5 (https=) | ||
| JP2005511592A5 (https=) | ||
| JP2007523185A5 (https=) | ||
| JP2007191486A5 (https=) | ||
| RU2000132188A (ru) | Производные эпотилонов, их синтез и применение | |
| JP2004520292A5 (https=) | ||
| JP2002520416A5 (https=) | ||
| RU2011127079A (ru) | Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с | |
| JP2020075939A5 (https=) | ||
| JP2005536553A5 (https=) | ||
| JP2010515731A5 (https=) | ||
| JP2006507220A5 (https=) | ||
| JP2002539156A5 (https=) | ||
| JP2005526836A5 (https=) | ||
| JP2001526218A5 (https=) | ||
| JP2007507494A5 (https=) | ||
| JP2005517677A5 (https=) | ||
| RU2005121908A (ru) | Производные зн-хиназолин-4-она | |
| RU2003134629A (ru) | Соединения цефема | |
| JP2004521150A5 (https=) | ||
| JP2004525178A5 (https=) | ||
| JP2008538362A (ja) | タンパク質の成熟の遮断を介して疾患を処置するための方法、タンパク質ジスルフィドイソメラーゼなどの分子シャペロンの機能を阻害する、またはグリコシル化を妨害する化合物、それらを含む薬学的組成物、および治療剤を同定するためのスクリーニング方法 |